Elgethun Capital Management Has $4.03 Million Holdings in Johnson & Johnson (JNJ)

Elgethun Capital Management raised its holdings in Johnson & Johnson (NYSE:JNJ) by 4.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,297 shares of the company’s stock after buying an additional 1,343 shares during the period. Johnson & Johnson comprises about 2.9% of Elgethun Capital Management’s holdings, making the stock its 8th largest position. Elgethun Capital Management’s holdings in Johnson & Johnson were worth $4,026,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of JNJ. Cornerstone Wealth Management LLC raised its stake in Johnson & Johnson by 10,307.6% in the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after buying an additional 2,473,105 shares in the last quarter. Bank of Montreal Can increased its position in shares of Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock worth $838,515,000 after purchasing an additional 1,833,622 shares in the last quarter. Summit Trail Advisors LLC increased its position in shares of Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,752,841 shares in the last quarter. Flossbach Von Storch AG increased its position in shares of Johnson & Johnson by 53.3% during the second quarter. Flossbach Von Storch AG now owns 3,553,636 shares of the company’s stock worth $431,198,000 after purchasing an additional 1,235,186 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado increased its position in shares of Johnson & Johnson by 212.7% during the second quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock worth $181,770,000 after purchasing an additional 1,019,002 shares in the last quarter. Institutional investors own 66.51% of the company’s stock.

JNJ opened at $145.91 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.99. The stock has a market cap of $391.78 billion, a PE ratio of 19.99, a PEG ratio of 2.28 and a beta of 0.59.



Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. During the same quarter last year, the company posted $1.90 earnings per share. The business’s revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 8.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

In related news, CAO Ronald A. Kapusta sold 8,441 shares of the firm’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the transaction, the chief accounting officer now owns 17,284 shares of the company’s stock, valued at $2,508,772.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Peter Fasolo sold 166,695 shares of the firm’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total value of $24,405,814.95. Following the transaction, the vice president now directly owns 155,540 shares in the company, valued at approximately $22,772,611.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 510,544 shares of company stock worth $74,414,877. Corporate insiders own 0.22% of the company’s stock.

A number of analysts have recently commented on the company. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 target price on shares of Johnson & Johnson in a research report on Friday, September 14th. Credit Suisse Group lifted their target price on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Citigroup lifted their target price on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research report on Monday, October 22nd. Finally, Raymond James lifted their target price on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $143.90.

TRADEMARK VIOLATION NOTICE: This news story was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://dakotafinancialnews.com/2018/12/07/elgethun-capital-management-has-4-03-million-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading: Different Types of Derivatives

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply